Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Dose-linearity of the pharmacokinetics of an intravenous [14 C]midazolam microdose in children.

van Groen BD, Vaes WH, Park BK, Krekels EHJ, van Duijn E, Kõrgvee LT, Maruszak W, Grynkiewicz G, Garner RC, Knibbe CAJ, Tibboel D, de Wildt SN, Turner MA.

Br J Clin Pharmacol. 2019 Jul 3. doi: 10.1111/bcp.14047. [Epub ahead of print]

PMID:
31269280
2.

Obsessive-Compulsive and Perseverative Behaviors in Huntington's Disease.

Oosterloo M, Craufurd D, Nijsten H, van Duijn E.

J Huntingtons Dis. 2019;8(1):1-7. doi: 10.3233/JHD-180335.

3.

Smartphone-based safety planning and self-monitoring for suicidal patients: Rationale and study protocol of the CASPAR (Continuous Assessment for Suicide Prevention And Research) study.

Nuij C, van Ballegooijen W, Ruwaard J, de Beurs D, Mokkenstorm J, van Duijn E, de Winter RFP, O'Connor RC, Smit JH, Riper H, Kerkhof A.

Internet Interv. 2018 May 5;13:16-23. doi: 10.1016/j.invent.2018.04.005. eCollection 2018 Sep.

4.

Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a 26 Al Microtracer Approach.

de Ligt R, van Duijn E, Grossouw D, Bosgra S, Burggraaf J, Windhorst A, Peeters PAM, van der Luijt GA, Alexander-White C, Vaes WHJ.

Clin Transl Sci. 2018 Nov;11(6):573-581. doi: 10.1111/cts.12579. Epub 2018 Jul 27.

5.

Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders.

Anderson KE, van Duijn E, Craufurd D, Drazinic C, Edmondson M, Goodman N, van Kammen D, Loy C, Priller J, Goodman LV.

J Huntingtons Dis. 2018;7(3):355-366. doi: 10.3233/JHD-180293.

6.

Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study.

Baake V, Coppen EM, van Duijn E, Dumas EM, van den Bogaard SJA, Scahill RI, Johnson H, Leavitt B, Durr A, Tabrizi SJ, Craufurd D, Roos RAC; Track-HD investigators.

Neuroimage Clin. 2018 Mar 27;19:66-70. doi: 10.1016/j.nicl.2018.03.033. eCollection 2018.

7.

Treatment results for severe psychiatric illness: which method is best suited to denote the outcome of mental health care?

de Beurs E, Blankers M, Delespaul P, van Duijn E, Mulder N, Nugter A, Swildens W, Tiemens BG, Theunissen J, van Voorst AFA, van Weeghel J.

BMC Psychiatry. 2018 Jul 13;18(1):225. doi: 10.1186/s12888-018-1798-4.

8.

Huntington's Disease Gene Expansion Carriers Are Aware of Their Degree of Apathy.

Baake V, van Duijn E, Roos RAC.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):183-187. doi: 10.1176/appi.neuropsych.18020031. Epub 2018 May 30.

PMID:
29843585
9.

Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P.

Mov Disord. 2018 Mar;33(3):499-500. doi: 10.1002/mds.27339. Epub 2018 Feb 20. No abstract available.

PMID:
29460975
10.

Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers.

van Duijn E, Vrijmoeth EM, Giltay EJ, Bernhard Landwehrmeyer G; REGISTRY investigators of the European Huntington's Disease Network.

J Affect Disord. 2018 Mar 1;228:194-204. doi: 10.1016/j.jad.2017.11.074. Epub 2017 Nov 15.

PMID:
29253686
11.

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P; members of the MDS Rating Scales Review Committee.

Mov Disord. 2018 Feb;33(2):208-218. doi: 10.1002/mds.27233. Epub 2017 Nov 23. Review.

PMID:
29168899
12.

Medical treatment of behavioral manifestations of Huntington disease.

van Duijn E.

Handb Clin Neurol. 2017;144:129-139. doi: 10.1016/B978-0-12-801893-4.00011-0. Review.

PMID:
28947111
13.

Subjective insomnia symptoms and sleep duration are not related to hypothalamic-pituitary-adrenal axis activity in older adults.

van Neijenhof RJGP, van Duijn E, Van Den Berg JF, de Waal MWM, van der Mast RC, Comijs HC.

J Sleep Res. 2018 Feb;27(1):40-46. doi: 10.1111/jsr.12570. Epub 2017 Jun 15.

14.

[Delayed diagnosis of Huntington's disease in a psychiatric setting].

Tak LM, Sizoo B, de Stegge BMA, Adema S, van Duijn E, Kremer B.

Tijdschr Psychiatr. 2017;59(6):372-375. Dutch.

15.

Disease stage and plasma levels of cytokines in Huntington's disease: A 2-year follow-up study.

Bouwens JA, van Duijn E, Cobbaert CM, Roos RAC, van der Mast RC, Giltay EJ.

Mov Disord. 2017 Jul;32(7):1103-1104. doi: 10.1002/mds.26950. Epub 2017 May 29. No abstract available.

PMID:
28556406
16.

Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

Gelderblom H, Wüstenberg T, McLean T, Mütze L, Fischer W, Saft C, Hoffmann R, Süssmuth S, Schlattmann P, van Duijn E, Landwehrmeyer B, Priller J.

PLoS One. 2017 Mar 21;12(3):e0173872. doi: 10.1371/journal.pone.0173872. eCollection 2017.

17.

Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations".

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2017 Mar;32(3):482. doi: 10.1002/mds.26954. Epub 2017 Mar 3. No abstract available.

PMID:
28256103
18.

Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism.

Mooij MG, van Duijn E, Knibbe CAJ, Allegaert K, Windhorst AD, van Rosmalen J, Hendrikse NH, Tibboel D, Vaes WHJ, de Wildt SN.

Clin Pharmacokinet. 2017 Oct;56(10):1185-1195. doi: 10.1007/s40262-017-0508-6.

19.

Suicidal ideation and subsequent completed suicide in both psychiatric and non-psychiatric populations: a meta-analysis.

Hubers AAM, Moaddine S, Peersmann SHM, Stijnen T, van Duijn E, van der Mast RC, Dekkers OM, Giltay EJ.

Epidemiol Psychiatr Sci. 2018 Apr;27(2):186-198. doi: 10.1017/S2045796016001049. Epub 2016 Dec 19.

PMID:
27989254
20.

Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington's disease.

Bouwens JA, van Duijn E, Cobbaert CM, Roos RA, van der Mast RC, Giltay EJ.

J Huntingtons Dis. 2016 Dec 15;5(4):369-377.

PMID:
27983562
21.

Correlates of sleep disturbances in depressed older persons: the Netherlands study of depression in older persons (NESDO).

Peters van Neijenhof RJG, van Duijn E, Comijs HC, van den Berg JF, de Waal MWM, Oude Voshaar RC, van der Mast RC.

Aging Ment Health. 2018 Feb;22(2):233-238. doi: 10.1080/13607863.2016.1247421. Epub 2016 Nov 9.

PMID:
27827534
22.

Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64].

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Oct;31:161. doi: 10.1016/j.parkreldis.2016.08.011. Epub 2016 Aug 25. No abstract available.

PMID:
27567724
23.

Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington's disease peripheral blood samples.

Mastrokolias A, Pool R, Mina E, Hettne KM, van Duijn E, van der Mast RC, van Ommen G, 't Hoen PA, Prehn C, Adamski J, van Roon-Mom W.

Metabolomics. 2016;12:137. Epub 2016 Jul 27.

24.

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Ferreira JJ, Mahlknecht P, Tumas V, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2016 Oct;31(10):1466-1478. doi: 10.1002/mds.26675. Review.

PMID:
27296904
25.

Suicidality in Huntington's Disease: A Qualitative Study on Coping Styles and Support Strategies.

Hubers AA, Hamming A, Giltay EJ, von Faber M, Roos RA, van der Mast RC, van Duijn E.

J Huntingtons Dis. 2016 May 31;5(2):185-98. doi: 10.3233/JHD-160188.

PMID:
27258585
26.

The impact of early human data on clinical development: there is time to win.

Swart P, Lozac'h F, Simon M, van Duijn E, Vaes WH.

Drug Discov Today. 2016 Jun;21(6):873-9. doi: 10.1016/j.drudis.2016.03.012. Epub 2016 Mar 29.

PMID:
27046542
27.

Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Apr;25:58-64. doi: 10.1016/j.parkreldis.2016.02.008. Epub 2016 Feb 11. Erratum in: Parkinsonism Relat Disord. 2016 Oct;31:161.

PMID:
26898966
28.

Screening for cognitive dysfunction in Huntington's disease with the clock drawing test.

Terwindt PW, Hubers AA, Giltay EJ, van der Mast RC, van Duijn E.

Int J Geriatr Psychiatry. 2016 Sep;31(9):1013-20. doi: 10.1002/gps.4412. Epub 2016 Jan 14.

PMID:
26766850
29.

Evaluation of benefit to patients of training mental health professionals in suicide guidelines: cluster randomised trial.

de Beurs DP, de Groot MH, de Keijser J, van Duijn E, de Winter RF, Kerkhof AJ.

Br J Psychiatry. 2016 May;208(5):477-83. doi: 10.1192/bjp.bp.114.156208. Epub 2015 Dec 17.

PMID:
26678866
30.

[Reaction on 'Psychiatric problems in a motor disorder: psychosis in Huntington's disease'].

van Duijn E.

Tijdschr Psychiatr. 2015;57(8):624. Dutch. No abstract available.

31.

Training mental health professionals in suicide practice guideline adherence: Cost-effectiveness analysis alongside a randomized controlled trial.

de Beurs DP, Bosmans JE, de Groot MH, de Keijser J, van Duijn E, de Winter RF, Kerkhof AJ.

J Affect Disord. 2015 Nov 1;186:203-10. doi: 10.1016/j.jad.2015.07.028. Epub 2015 Jul 26.

32.

Irritability in a Prospective Cohort of Huntington's Disease Mutation Carriers.

Bouwens JA, van Duijn E, van der Mast RC, Roos RA, Giltay EJ.

J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):206-12. doi: 10.1176/appi.neuropsych.14030051. Epub 2015 Jun 12.

PMID:
26067436
33.

Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.

Vlaming ML, van Duijn E, Dillingh MR, Brands R, Windhorst AD, Hendrikse NH, Bosgra S, Burggraaf J, de Koning MC, Fidder A, Mocking JA, Sandman H, de Ligt RA, Fabriek BO, Pasman WJ, Seinen W, Alves T, Carrondo M, Peixoto C, Peeters PA, Vaes WH.

Clin Pharmacol Ther. 2015 Aug;98(2):196-204. doi: 10.1002/cpt.131. Epub 2015 May 19.

PMID:
25869840
34.

Comparing Methods to Denote Treatment Outcome in Clinical Research and Benchmarking Mental Health Care.

de Beurs E, Barendregt M, de Heer A, van Duijn E, Goeree B, Kloos M, Kooiman K, Lionarons H, Merks A.

Clin Psychol Psychother. 2016 Jul;23(4):308-18. doi: 10.1002/cpp.1954. Epub 2015 Apr 7.

PMID:
25847057
35.

Anxiety in Huntington's Disease.

Dale M, van Duijn E.

J Neuropsychiatry Clin Neurosci. 2015 Fall;27(4):262-71. doi: 10.1176/appi.neuropsych.14100265. Epub 2015 Mar 24. Review.

PMID:
25803201
36.

Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies.

Callaghan J, Stopford C, Arran N, Boisse MF, Coleman A, Santos RD, Dumas EM, Hart EP, Justo D, Owen G, Read J, Say MJ, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Bachoud-Levi AC, Bourdet C, van Duijn E, Craufurd D.

J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):59-64. doi: 10.1176/appi.neuropsych.13070169.

PMID:
25716488
37.

The effect of an e-learning supported Train-the-Trainer programme on implementation of suicide guidelines in mental health care.

de Beurs DP, de Groot MH, de Keijser J, Mokkenstorm J, van Duijn E, de Winter RF, Kerkhof AJ.

J Affect Disord. 2015 Apr 1;175:446-53. doi: 10.1016/j.jad.2015.01.046. Epub 2015 Jan 24.

38.

Do Attachment Style and Emotion Regulation Strategies Indicate Distress in Predictive Testing?

van der Meer LB, van Duijn E, Giltay EJ, Tibben A.

J Genet Couns. 2015 Oct;24(5):862-71. doi: 10.1007/s10897-015-9822-z. Epub 2015 Feb 3.

39.

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood.

Mastrokolias A, Ariyurek Y, Goeman JJ, van Duijn E, Roos RA, van der Mast RC, van Ommen GB, den Dunnen JT, 't Hoen PA, van Roon-Mom WM.

Eur J Hum Genet. 2015 Oct;23(10):1349-56. doi: 10.1038/ejhg.2014.281. Epub 2015 Jan 28.

40.

Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.

Garner CR, Park KB, French NS, Earnshaw C, Schipani A, Selby AM, Byrne L, Siner S, Crawley FP, Vaes WH, van Duijn E, deLigt R, Varendi H, Lass J, Grynkiewicz G, Maruszak W, Turner MA.

Br J Clin Pharmacol. 2015 Jul;80(1):157-67. doi: 10.1111/bcp.12597. Epub 2015 Jun 1.

41.

Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease and its association with depressive symptoms and suicidality.

Hubers AA, van der Mast RC, Pereira AM, Roos RA, Veen LJ, Cobbaert CM, van Duijn E, Giltay EJ.

J Neuroendocrinol. 2015 Mar;27(3):234-44. doi: 10.1111/jne.12255.

PMID:
25565388
42.

Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept.

Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, Spaans E, Fabriek BO, Sandman H, Grossouw D, Hanff LM, Janssen PJ, Koch BC, Tibboel D, de Wildt SN.

Clin Pharmacokinet. 2014 Nov;53(11):1045-51. doi: 10.1007/s40262-014-0176-8.

43.

Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range.

van Duijn E, Sandman H, Grossouw D, Mocking JA, Coulier L, Vaes WH.

Anal Chem. 2014 Aug 5;86(15):7635-41. doi: 10.1021/ac5015035. Epub 2014 Jul 25.

PMID:
25033319
44.

Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's disease.

Bouwens JA, Hubers AA, van Duijn E, Cobbaert CM, Roos RA, van der Mast RC, Giltay EJ.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1248-56. doi: 10.1016/j.euroneuro.2014.05.004. Epub 2014 May 20.

PMID:
24957738
45.

Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).

van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB; European Huntington's Disease Network Behavioural Phenotype Working Group.

J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1411-8. doi: 10.1136/jnnp-2013-307343. Epub 2014 May 14.

PMID:
24828898
46.

Substrate occupancy at the onset of oligomeric transitions of DegP.

Thompson NJ, Merdanovic M, Ehrmann M, van Duijn E, Heck AJ.

Structure. 2014 Feb 4;22(2):281-90. doi: 10.1016/j.str.2013.11.010. Epub 2013 Dec 26.

47.

Sizing up large protein complexes by electrospray ionisation-based electrophoretic mobility and native mass spectrometry: morphology selective binding of Fabs to hepatitis B virus capsids.

Bereszczak JZ, Havlik M, Weiss VU, Marchetti-Deschmann M, van Duijn E, Watts NR, Wingfield PT, Allmaier G, Steven AC, Heck AJ.

Anal Bioanal Chem. 2014 Feb;406(5):1437-46. doi: 10.1007/s00216-013-7548-z. Epub 2013 Dec 20.

48.

Offspring of a parent with genetic disease: childhood experiences and adult psychological characteristics.

van der Meer L, van Duijn E, Wolterbeek R, Tibben A.

Health Psychol. 2014 Dec;33(12):1445-53. doi: 10.1037/a0034530. Epub 2013 Nov 25.

PMID:
24274803
49.

Reducing patients' suicide ideation through training mental health teams in the application of the Dutch multidisciplinary practice guideline on assessment and treatment of suicidal behavior: study protocol of a randomized controlled trial.

de Beurs DP, de Groot MH, Bosmans JE, de Keijser J, Mokkenstorm J, Verwey B, van Duijn E, de Winter RF, Kerkhof AJ.

Trials. 2013 Nov 6;14:372. doi: 10.1186/1745-6215-14-372.

50.

Structure and activity of the RNA-targeting Type III-B CRISPR-Cas complex of Thermus thermophilus.

Staals RHJ, Agari Y, Maki-Yonekura S, Zhu Y, Taylor DW, van Duijn E, Barendregt A, Vlot M, Koehorst JJ, Sakamoto K, Masuda A, Dohmae N, Schaap PJ, Doudna JA, Heck AJR, Yonekura K, van der Oost J, Shinkai A.

Mol Cell. 2013 Oct 10;52(1):135-145. doi: 10.1016/j.molcel.2013.09.013.

Supplemental Content

Loading ...
Support Center